Sarepta’s Elevidys secures US label expansion for DMD
Sarepta’s stock rose by over 36% following the positive news of the FDA expanding the gene therapy’s US label.
Sarepta’s stock rose by over 36% following the positive news of the FDA expanding the gene therapy’s US label.
What's Your Reaction?
